🩺 Abbott Laboratories (ABT) Stock Analysis: Can a Dividend King Turn Exact Sciences Into Its Next Growth Engine?

Insider Buying, 16x Forward Earnings, and a $21 Billion Oncology Bet 🩺💸

Inside the Exact Sciences Acquisition, FreeStyle Libre 3 Moats, and a 100-Year Dividend Foundation

NYSE: ABT • $90.53 (+3.07%)

As of June 23, 2026

Abbott Laboratories is not flashy.

It isn't the hottest AI stock.

It doesn't promise to colonize Mars.

And nobody is day-trading glucose monitors on social media.

Yet Abbott has quietly become one of the most durable healthcare franchises on Earth.

Founded in 1888, the company now spans four major healthcare segments:

• Medical Devices

• Diagnostics

• Nutrition

• Established Pharmaceuticals

More importantly, it recently completed a transformational acquisition that could reshape its long-term growth trajectory.

And insiders appear to be paying attention.

🚀 FUNanc1al Atomic Statements

🧬 The Diagnostic Flywheel Principle™

The most valuable healthcare platforms don't simply diagnose disease—they create recurring ecosystems of testing, monitoring, and follow-up care.

👑 The Dividend King Insulation Rule™

A century of uninterrupted dividends doesn't eliminate risk. It simply proves management has survived more crises than most investors can remember.

🩺 The Healthcare Plumbing Principle™

The most powerful healthcare companies rarely make headlines. They quietly become the infrastructure through which modern medicine operates.

🕵️ Trigger #1: Insiders Just Opened Their Wallets

When evaluating healthcare companies, one useful question is:

What are the people running the business doing with their own money?

Recently, several Abbott insiders answered that question.

EVP & CFO Philip Boudreau

• Purchased 2,200 shares

• Average price: $91.50

• Investment: approximately $201,000

Director Daniel J. Starks

• Purchased 10,000 shares

• Average price: $92.65

• Investment: approximately $927,000

Director John G. Stratton

• Purchased 2,000 shares

• Average price: $86.82

• Investment: approximately $174,000

Combined purchases exceeded:

$1.3 million

Not life-changing for billionaires.

But meaningful enough to deserve attention.

🏦 Trigger #2: Institutions Already Love This Stock

Unlike many smaller companies we cover, Abbott is not undiscovered.

Far from it.

Institutional ownership sits at approximately:

82.7%

while institutions control roughly:

83.1% of the float.

Major holders include:

• BlackRock

• Vanguard

• State Street

• Capital Research

• Wellington

This is not a hidden gem.

It's a healthcare blue chip.

And Wall Street knows it.

For Abbott Laboratories (ABT)'s Institutional Ownership breakdown, 🔍 see here.

📉 The Bear Population Appears Endangered

Short sellers have largely abandoned Abbott.

Current short interest:

1.27%

Days to cover:

1.66

In other words:

Very few investors appear willing to bet aggressively against the company.

That doesn't guarantee future returns.

But it does suggest a lack of meaningful bearish conviction.

🩺 THE ABT CAPITAL STRUCTURE

🐋 Institutional Ownership: 82.67%

📊 Float Controlled by Institutions: 83.08%

📉 Short Interest: 1.27%

⏳ Days To Cover: 1.66

👑 Consecutive Years of Dividend Increases: 50+

🎯 Trigger #3: Analysts Continue To Like The Story

Wall Street remains broadly constructive.

Consensus rating:

Buy / Moderate Buy

Analyst breakdown:

• 19 Buy / Strong Buy

• 4 Hold

• 1 Sell

Average target range:

$116.54-$129.17

Potential upside:

29%-43%

Analysts also project approximately:

10.4% earnings growth

over the coming years.

Not hypergrowth.

But solid.

Especially for a healthcare giant.

💰 Trigger #4: Valuation Looks Reasonable

Abbott isn't cheap.

But it isn't expensive either.

That's a useful distinction.

Current metrics include:

Trailing P/E

24.6x

Forward P/E

16.0x

PEG Ratio

1.30

Price/Sales

3.40

Price/Book

2.94

EV/EBITDA

15.2

Most importantly:

Forward P/E has compressed dramatically.

Just one year ago, investors were paying roughly:

26x forward earnings.

Today:

16x.

That is a major rerating.

Bonus: The stock trades 36.5% below its ATH of $142.60 reached in December 2021. While past highs offer no guarantee of future returns, they do illustrate how dramatically sentiment has cooled. Investors are no longer paying peak-pandemic multiples for the same company—and arguably a stronger one.

In a market where many AI names trade at eye-watering valuations, Abbott increasingly resembles a classic:

GARP

Growth At a Reasonable Price.

🎭 Abbott & Costello Meet Wall Street

Bulls see:

• FreeStyle Libre

• Cancer diagnostics

• Dividend growth

• Structural heart devices

• A reasonable valuation

Bears see:

• Acquisition dilution

• Integration costs

• A valuation that still lacks a margin of safety

The debate increasingly resembles Abbott & Costello's famous routine.

Who's on first?

Apparently Exact Sciences.

📈 Trigger #5: Q1 2026 Was Better Than Headlines Suggest

Abbott reported:

Revenue

$11.16 billion

Revenue Growth

+7.8%

Adjusted EPS

$1.15

Both revenue and earnings exceeded expectations.

More importantly, the company's core growth engines remain healthy.

Medical Devices grew:

+13.2%

led by:

• Rhythm Management

• Electrophysiology

• Heart Failure

Established Pharmaceuticals grew:

+13.2%

with strong international performance.

Meanwhile, Diagnostics gained an entirely new growth lever.

 👉 Want the full picture? Dive into Abbott Laboratories (ABT)'s financials here.

🧬 Trigger #6: The Exact Sciences Acquisition Changes The Story

On March 23, 2026, Abbott closed its:

$21 billion acquisition of Exact Sciences

This is not a minor bolt-on transaction.

It is a strategic shift.

The deal adds:

• Cologuard®

• Cancerguard®

• oncology diagnostics

• cancer screening infrastructure

to Abbott's already extensive diagnostics platform.

Some investors immediately focused on the downside:

Approximately $0.20 EPS dilution

Fair enough.

But focusing exclusively on dilution may miss the larger picture.

Cologuard remains the market leader in non-invasive colorectal cancer screening.

Meanwhile, Cancerguard represents one of the more intriguing multi-cancer detection platforms currently available.

Abbott isn't simply buying products.

It is buying an oncology ecosystem.

And healthcare ecosystems tend to become more valuable over time.

🧬 The Diagnostic Flywheel In Action

The Exact Sciences acquisition perfectly illustrates what we call:

The Diagnostic Flywheel Principle™

The most valuable healthcare platforms don't simply diagnose disease.

They create recurring ecosystems of:

• screening;

• monitoring;

• testing;

• follow-up care;

• physician relationships.

Each layer reinforces the next.

That's a powerful model.

📱 Trigger #7: FreeStyle Libre Remains A Monster Growth Engine

Abbott's crown jewel may still be:

FreeStyle Libre 3

its continuous glucose monitoring platform.

Recent clinical results showed Libre 3 outperforming traditional finger-stick monitoring among Type 2 diabetes patients.

The implications are enormous.

Diabetes remains one of the largest chronic healthcare challenges globally.

Better outcomes.

Greater convenience.

Improved compliance.

These are exactly the characteristics that create durable healthcare moats.

🩸 The Fingerstick Retirement Plan

FreeStyle Libre continues making life easier for millions of people.

Somewhere, an old finger-prick testing device is quietly updating its résumé.

👑 Trigger #8: The Dividend King Foundation

Many companies promise durability.

Abbott has demonstrated it.

The company has:

Paid dividends for more than 100 consecutive years

and increased those dividends for:

More than 50 consecutive years.

That places Abbott among a tiny group of corporate royalty:

Dividend Kings

No, dividends don't eliminate risk.

Nothing does.

But surviving:

• recessions;

• wars;

• inflation;

• pandemics;

• market crashes;

for over a century says something important about the business model.

☎️ The 100-Year Dividend Test

Abbott was distributing dividends when telephones were considered cutting-edge technology.

That's either incredibly reassuring or mildly terrifying.

Perhaps both.

⚠️ Key Risks

No straight shooters.

Abbott faces real challenges.

💸 Exact Sciences Integration

Large acquisitions occasionally disappoint.

Execution matters.

📉 EPS Dilution

The acquisition reduces near-term earnings.

Management must prove long-term benefits outweigh short-term pain.

🥤 Nutrition Segment Weakness

Growth has slowed.

Recent pricing actions have pressured volumes.

🧪 Diagnostics Volatility

Testing businesses can experience seasonal fluctuations.

💰 Valuation

Reasonable.

Not cheap.

Investors hoping for a screaming bargain may want more patience.

💡💡💡 Curious about another deep oil exploration play? (joke)
Check our takes on UnitedHealth Group or even Oscar Health.

📌 Signal Extract

🧬 The Diagnostic Flywheel Principle™

The most valuable healthcare platforms don't simply diagnose disease—they create recurring ecosystems of testing, monitoring, and follow-up care.

🎯 High-Conviction Takeaway

👑 The Dividend King Insulation Rule™

A century of uninterrupted dividends doesn't eliminate risk. It simply proves management has survived more crises than most investors can remember.

⚡ Quick Take / TL;DR

Positives

✅ Exact Sciences expands oncology exposure

✅ FreeStyle Libre remains a powerful growth engine

✅ Insider buying near current prices

✅ Forward P/E compressed to ~16x

✅ Dividend King status

✅ Strong diversification across four healthcare segments

✅ Analysts see meaningful upside

Risks

❌ Exact Sciences integration risk

❌ Near-term EPS dilution

❌ Nutrition segment softness

❌ Diagnostics volatility

❌ Valuation is reasonable but not deeply discounted

❓ FAQ

Is Abbott cheap?

Not really.

At roughly 16x forward earnings, it appears reasonably valued rather than deeply undervalued.

Why are insiders buying?

Insiders may believe the market is underestimating the long-term benefits of the Exact Sciences acquisition and the continued strength of Abbott's medical device portfolio.

What is Abbott's biggest growth driver?

Today, FreeStyle Libre remains one of the company's most important growth engines.

Longer term, oncology diagnostics could become increasingly significant.

Why does the dividend matter?

The dividend itself isn't the story.

The durability required to maintain and increase it for more than 100 years is.

What is the biggest risk?

Execution.

The Exact Sciences acquisition must deliver the growth and synergies management expects.

🌎 Food for Thought: The Cross-Hub Connection

Healthcare investing is ultimately an investment in human longevity.

Whether through cancer screening, diabetes management, heart health, nutrition, or prevention, Abbott sits at the intersection of several long-term themes we follow closely at FUNanc1al.

Better healthcare doesn't merely create shareholder value.

It creates:

• more birthdays;

• more family dinners;

• more World Cups;

• more sunsets;

• and more opportunities to enjoy life itself.

That may be the most important return on investment of all.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al — part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he now blends sharp insights with a twist of humor to help readers laugh, learn, live better lives, and invest a little wiser. When not decoding insider buys or poking fun at earnings calls, he's building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

Final Verdict 🩺

Abbott Laboratories is unlikely to double overnight.

That's not the point.

What investors receive is:

• a Dividend King;

• a diversified healthcare powerhouse;

• a growing oncology platform;

• a dominant diabetes franchise;

• insider buying;

• and a valuation that finally looks reasonable.

At roughly 16x forward earnings, Abbott increasingly resembles a classic GARP opportunity.

Not a screaming bargain.

Not a speculative moonshot.

Just a durable compounding machine.

FunStock Index™: 7.49 / 10 🩺

Starter position?

Reasonable.

Back up the truck?

Not quite yet.

Add on dips?

Absolutely worth considering.

And while bulls and bears continue performing Abbott & Costello routines on financial television, Abbott will likely keep doing what it has done since 1888:

Quietly improving healthcare.

And mailing dividend checks.